Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Kidney Cancer
Interventions
DRUG

Sorafenib

Sorafenib

DRUG

RAD001

RAD001

Trial Locations (11)

29210

South Carolina Oncology Associates, PA, Columbia

29303

Spartanburg Regional Medical Center, Spartanburg

30060

Wellstar Cancer Research, Marietta

30501

Northeast Georgia Medical Center, Gainesville

32804

Florida Hospital Cancer Institute, Orlando

37023

Tennessee Oncology, PLLC, Nashville

40207

Baptist Hospital East, Louisville

Norton Cancer Institute, Louisville

45242

Oncology Hematology Care, Cincinnati

64132

Research Medical Center, Kansas City

07960

Hematology Oncology Associates of Northern NJ, Morristown

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER